Obesity and endocrine therapy: Host factors and breast cancer outcome

Breast

Volumn 22, Issue S2, 2013, Pages

  Goodwin, Pamela J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Adjuvant; Aromatase inhibitor; Body mass index; Breast cancer; Effectiveness

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; GOSERELIN; LETROZOLE; SOMATOMEDIN C; TAMOXIFEN; ZOLEDRONIC ACID;

ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; INTRACELLULAR SIGNALING; MONOTHERAPY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RISK ASSESSMENT;

ADJUVANT; AROMATASE INHIBITOR; BODY MASS INDEX; BREAST CANCER; EFFECTIVENESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; OBESITY; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84884715666     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.008     Document Type: Article

References (31)

1. Protani M., Coory M., Martin J.H. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010, 123:627-635.
2. Niraula S., Ocana A., Ennis M., Goodwin P.J. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 2012, 134:769-781.
3. Sparano J.A., Wang M., Zhao F., Stearns V., Martino S., Ligibel J.A., et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012, 118:5937-5946.
4. Khandekar M.J., Cohen P., Spiegelman B.M. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011, 11:886-895.
5. Geisler J., Haynes B., Ekse D., Dowsett M., Lonning P.E. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. JSteroid Biochem Mol Biol 2007, 104:27-34.
6. Simpson E.R., Mendelson C.R. Effect of aging and obesity on aromatase activity of human adipose cells. Am J Clin Nutr 1987, 45(1 Suppl.):290-295.
7. Morris P.G., Hudis C.A., Giri D., Morrow M., Falcone D.J., Zhou X.K., et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011, 4:1021-1029.
8. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. JClin Oncol 2002, 20:42-51.
9. Fagan D.H., Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. JMammary Gland Biol Neoplasia 2008, 13:423-429.
10. Hvidtfeldt U.A., Gunter M.J., Lange T., Chlebowski R.T., Lane D., Farhat G.N., et al. Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev 2012, 21:1203-1212.
11. Cauley J.A., Gutai J.P., Kuller L.H., LeDonne D., Powell J.G. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989, 129:1120-1131.
12. Rock C.L., Flatt S.W., Laughlin G.A., Gold E.B., Thomson C.A., Natarajan L., et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:614-620.
13. Geisler J., Helle H., Ekse D., Duong N.K., Evan D.B., Nordbø Y., et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 2008, 14:6330-6335.
14. Folkerd E.J., Dixon J.M., Renshaw L., A'Hern R.P., Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. JClin Oncol 2012, 30:2977-2980.
15. Diorio C., Lemieux J., Provencher L., Hogue J.C., Vachon E. Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Res Treat 2012, 136:573-579.
16. Desta Z., Kreutz Y., Nguyen A.T., Li L., Skaar T., Kamdem L.K., et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 2011, 90:693-700.
17. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. JClin Oncol 2010, 28:3784-3796.
18. Sestak I., Distler W., Forbes J.F., Dowsett M., Howell A., Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. JClin Oncol 2010, 28:3411-3415.
19. Pfeiler G., Konigsberg R., Fesl C., Mlineritsch B., Stoeger H., Singer C.F., et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. JClin Oncol 2011, 29:2653-2659.
20. Ewertz M., Gray K.P., Regan M.M., Ejlertsen B., Price K.N., Thürlimann B., et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial. JClin Oncol 2012, 30:3967-3975.
21. Seynaeve C., Hille E., Hasenburg A., Rea D., Markopoulos C., Hozumi Y., et al. The impact of body mass index on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer patients: exploratory analysis from the TEAM study. Cancer Res 2010, 70(24 Suppl.). Abstr nrS2-S3.
22. Gnant M., Mlineritsch B., Stoeger H., Luschin-Ebengreuth G., Heck D., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641.
23. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
24. Forward D.P., Cheung K.L., Jackson L., Robertson J.F. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004, 90:590-594.
25. Michaud L.B., Buzdar A.U., Rubin S., Steinberg M., Yin H., Aaronson L., et al. The efficacy of anastrozole is not dependent upon body mass index in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2002, 21. [abstr 219].
26. Schmid P., Possinger K., Bohm R., Chaudri V., Verbeek V., Grosse Y., et al. Body mass index as predictive parameter for response and time to progression in advanced breast cancer patients treated with letrozole or megestrol acetate. Proc Am Soc Clin Oncol 2000, 19. [abstr 398].
27. Takada M., Saji S., Masuda N., Kuroi K., Sato N., Takei H., et al. Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast 2012, 21:40-45.
28. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
29. Amir E., Seruga B., Niraula S., Carlsson L., Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. JNatl Cancer Inst 2011, 103:1299-1309.
30. Eisen A., Trudeau M., Shelley W., Messersmith H., Pritchard K.I. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008, 34:157-174.
31. Sestak I., Cuzick J., Sapunar F., Eastell R., Forbes J.F., Bianco A.R., et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008, 9:866-872.